Cargando…
Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris
In pemphigus vulgaris (PV), IgG autoantibodies against the ectodomain of desmoglein 3 (Dsg3) have been shown to be directly responsible for the loss of keratinocyteadhesion. The aim of the present study was to study the effect of the B cell depleting anti-CD20 monoclonal antibody, rituximab, on the...
Autores principales: | Müller, Ralf, Hunzelmann, Nicolas, Baur, Vera, Siebenhaar, Guido, Wenzel, Elke, Eming, Rüdiger, Niedermeier, Andrea, Musette, Philippe, Joly, Pascal, Hertl, Michael |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909726/ https://www.ncbi.nlm.nih.gov/pubmed/20671975 http://dx.doi.org/10.1155/2010/321950 |
Ejemplares similares
-
Faster IgG4 Depletion Kinetics Observed for Anti-Desmoglein 3 Autoantibodies Following Rituximab Treatment in Patients with Pemphigus Vulgaris
por: BOCH, Katharina, et al.
Publicado: (2022) -
Identification of Autoreactive B Cell Subpopulations in Peripheral Blood of Autoimmune Patients With Pemphigus Vulgaris
por: Pollmann, Robert, et al.
Publicado: (2019) -
IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab
por: Font, Guillaume, et al.
Publicado: (2022) -
Rituximab in the Treatment of Pemphigus Vulgaris
por: Zakka, Labib R., et al.
Publicado: (2012) -
Pemphigus: Current and Future Therapeutic Strategies
por: Didona, Dario, et al.
Publicado: (2019)